Preliminary results from the CORE open label extension (OLE) trial of olezarsen in patients with severe hypertriglyceridaemia (sHTG) have shown durable reductions in median TG levels through up to 12 months of follow up.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
